AMSTERDAM, Sept. 30, 2015 /PRNewswire/ -- VIDA Diagnostics, Inc. ("VIDA"), the leader in precision pulmonary imaging, today announced it has received the European Respiratory Society's Product of Outstanding Interest (POINT) award. The honor recognizes innovation in the area of respiratory healthcare, with a focus on solutions solving clinical care challenges.
"We are delighted and honored to receive the POINT award here at ERS," said Susan A. Wood, Ph.D, President and CEO of VIDA. "We thank the ERS for recognizing and supporting our mission of improving patient outcomes through precision imaging."
VIDA's solution transforms raw imaging data into concise, quantified measures that inform highly personalized care decisions. For example, VIDA's Lung Volume Reduction (LVR) workflow provides individual metrics for fissure integrity, disease severity by lobe, and disease heterogeneity, all of which are critical input in selecting and planning therapy. VIDA is demonstrating this workflow and others at ERS, with its next-generation viewing platform, VIDA|vision™.
"VIDA's solution captures the personalized medicine theme of ERS," said Felix Herth, MD, Ph.D, Chairman, Department of Pneumology and Critical Care Medicine at ThoraxKlinik, University of Heidelberg. "An informed decision process is increasingly necessary as pulmonary diagnoses and therapeutics become more personalized. VIDA takes into account the uniqueness of the patient and helps us plan a unique care path to match."
VIDA is a leader in precision pulmonary imaging to aid early detection, evaluation, and treatment planning of lung diseases including COPD, emphysema, lung cancer, and asthma. FDA approved, CE, CMDCAS and TGA certified, VIDA's software and services are routinely used in clinical practice, along with academic, device, and pharmaceutical clinical trials. VIDA's offices are located in Coralville, IA and Minneapolis, MN.
SOURCE VIDA Diagnostics, Inc.